Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
MindBio Therapeutics Corp. reports a significant breakthrough in its Phase 2A clinical trials, with patients experiencing a sustained 62.8% reduction in depressive symptoms three months after treatment with microdosing LSD. The trials showcase the treatment’s safety and effectiveness, positioning MindBio as a pioneer in at-home psychedelic treatments for depression, which may offer a more cost-effective and less burdensome alternative to traditional clinic-based therapies.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.
